Tuesday, April 05, 2022 9:44:14 AM
HL, my argument is that the revenue grows at a snail’s pace. I’ve been in this for several years. My first year, I bought at 0008 and rode it to .0015. Instead of selling I held on to only have it drop back. I believed in their growth predictions and share buybacks which did not materialize. In this industry, there should be exponential growth and there is not. I’m still holding, but very disappointed to say the least. I hope the advisors bring new prospects to this company. JMHO
The Old Owl
The Old Owl
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
